TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02348541

Intervention type: DEVICE
Group type: OTHER
Intervention: CollaGUARD
Study: NCT03037411

Intervention type: DEVICE
Intervention: Peripheral stenting
Description: stent implantation during the index procedure
Study: NCT01397474

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PPTFM
Description: Peripheral Perfusion Targeted Fluid Management
Study: NCT00467259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Transdermal System
Description: Testosterone patch, 300 mcg/day, change patch twice a week for 52 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Description: placebo patch, changed twice a week for 52 weeks
Study: NCT04602455

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Care Program through Heartfulness
Description: A four-week Self-Care program through Heartfulness will be offered to participants in the Heartfulness group. This would include a daily practice of relaxation tools for 15 minutes a day using an app and once a week webinar for 30 minutes. Guided relaxation and meditation sessions will be offered to the participants during the intervention weeks. These virtual sessions were conducted by Heartfulness Champions and certified trainers from Heartfulness Institute.
Study: NCT05076474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orlistat 60mg Cap
Description: Subjects completed a 5-day run-in period (baseline) and then were randomized to receive the first of 3 treatments; each treatment period lasted 10 days followed by a 4-day washout period between treatments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orlistat 60mg Cap
Description: Subjects completed a 5-day run-in period (baseline) and then were randomized to receive the first of 3 treatments; each treatment period lasted 10 days followed by a 4-day washout period between treatments.
Study: NCT05984446

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real-rTMS
Description: Each subject will undergo 4 rTMS sessions using a 70-mm figure-eight coil (20Hz for 25 minutes). Target localization will be performed with a stereotaxic neuronavigation system.
Study: NCT05076474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orlistat 60mg Cap
Description: Subjects completed a 5-day run-in period (baseline) and then were randomized to receive the first of 3 treatments; each treatment period lasted 10 days followed by a 4-day washout period between treatments.
Study: NCT03630003

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MOCS
Description: The device consists of a tablet computer that can produce visual and auditory components designed to improve subject knowledge about setting and communication, mounted on a table or at the side of the bed in a place that is visible to the subject.~The Arduino will be connected to switches/buttons and implemented in a 3D-printed platform.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-use interview
Description: The Study team conducts an interview with participants to evaluate their experience with use of the MOCS device.
Study: NCT05984446

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham-rTMS
Description: The sham condition will match the real-rTMS protocol, but a sham coil will be used.
Study: NCT03404791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAR-200
Description: TAR-200 will be placed for 21-day dosing cycles, with up to 7 doses per participant.
Study: NCT01716598

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IPS System
Description: TLD Therapy will be achieved bronchoscopically.
Study: NCT01096264

Intervention type: OTHER
Group type: OTHER
Intervention: SSI and SphygmoCor® evaluations
Description: * SSI evaluation need Aixplorer vascular ultrasound machine (available in our department) with 8 MHz linear array probe applied on the carotid and femoral artery.~* SphygmoCor® evaluation used pressure captors on carotid and femoral sites to record the intra-arterial pressure wave time delay after QRS wave. After distance calculation between the two sites, Aortic PWV can be derived.
Study: NCT02646618

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone
Description: A smartphone is needed to use MyFitnessPal for all participants and to access Twitter for the Get Social participants
Study: NCT04003324

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Op is Top - using feedback from the Activator to reduce sedentary behavior in older adults
Description: Participants will receive a self-monitoring tool (i.e. the Activator) aimed at the reduction of sedentary behavior. Participants will be able to use the self-monitoring tool for four weeks. Apart from that, participants will receive general sedentary behavior information and an explanation on how to use the self-monitoring tool.
Study: NCT02795884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intercalation therapy using pemetrexed, cisplatin and erlotinib
Description: During the intercalation phase of the initial 12-week period, erlotinib is to be orally administered at the dose of 150 mg daily from Day 8 to Day 21 at every cycle of 21 days. During the maintenance phase after 12 weeks, it is orally administered at the cycle of 28 days without a wash-out period at the dose of 150 mg daily for one year. The combination of pemetrexed and cisplatin will be administered for 4 cycles in total by each cycle of 21 days, and it is to be administered by intravenous (IV) infusion on every Day 1. Pemetrexed 500 mg/m2 will be diluted in 100 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 10 minutes. Cisplatin 75 mg/m2 will be diluted in 150 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 10 to 15 minutes. The combination of pemetrexed and cisplatin will be administered for 4 cycles in total by each cycle of 21 days, and it is to be administered by intravenous (IV) infusion on every Day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine, cisplatin
Description: Vinorelbine 25mg/m2 will be diluted in 50 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 6 to 10 minutes and then wash the catheter using 100 ml of 0.9% saline solution. Cisplatin 75 mg/m2 will be diluted in 150 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 10 to 15 minutes.
Study: NCT00872248

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Description: Procedures of spinal anesthesia with bupivacaine 0.5%, 10-15mg

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural anesthesia
Description: Procedures of epidural anesthesia with ropivacaine 0.75%, 75-120mg
Study: NCT01123174

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ALGOS algorithm of case management
Description: If the subject survives one 1st SA (first attempter): he leaves the center where he was included with a chart resource (crisis card) which contains addresses of the Web sites of associations of prevention of the suicide, as well as an accessible phone number 24/24h.~If the subject is not a first attempter : he will be recontacted on the telephone between the 10th and the 21st day following the SA. If the subject is not contacted or little observing in the plan of care, it will receive a series of postcards then regularly, with 4 recoveries: to 2, 3, 4 and 5 months after the attempt.
Study: NCT02461979

Intervention type: OTHER
Group type: OTHER
Intervention: The VDR genotype
Description: The VDR genotype will determined by polymerase chain reaction (PCR) amplication and restriction length fragment polymorphisms.

Intervention type: OTHER
Group type: OTHER
Intervention: The VDR genotype
Description: The VDR genotype will determined by polymerase chain reaction (PCR) amplication and restriction length fragment polymorphisms.

Intervention type: OTHER
Group type: OTHER
Intervention: The VDR genotype
Description: The VDR genotype will determined by polymerase chain reaction (PCR) amplication and restriction length fragment polymorphisms.
Study: NCT04489355

Intervention type: PROCEDURE
Intervention: coronary artery bypass graft (CABG) with surgical ventricular restoration (SVR) and mitral repair (MR)

Intervention type: PROCEDURE
Intervention: coronary artery bypass graft (CABG) with surgical ventricular restoration (SVR) and mitral repair (MR)

Intervention type: PROCEDURE
Intervention: coronary artery bypass graft (CABG) with surgical ventricular restoration (SVR) and mitral repair (MR)

Intervention type: PROCEDURE
Intervention: coronary artery bypass graft (CABG) with surgical ventricular restoration (SVR) and mitral repair (MR)
Study: NCT02646774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin
Description: Injection
Study: NCT02874014

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionation Proton beam therapy with Concurrent Treatment of the Prostate and Pelvic Nodes
Study: NCT03664791

Intervention type: PROCEDURE
Intervention: Vanguard Rocc
Description: Patient operated with the Vanguard Rocc knee prosthesis
Study: NCT04390724

Intervention type: DEVICE
Intervention: Y90 radioembolization
Description: Patients with HCC who are eligible to receive standard-of-care Y90 radioembolization and are hepatic resection candidates with inadequate future liver remnant
Study: NCT02364557

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Description: Patients receive 1, 3, or 5 fractions of radiation, beginning within 6 weeks of study entry.~* For metastases in the peripheral lung, patients receive a single fraction of 30 Gy or 3 fractions for a total of 45 Gy.~* For a single liver metastases, patients receive a single fraction of 30 Gy.~* For metastases in the abdominal-pelvic or liver (\>1), patients receive 3 fractions for a total of 45 Gy.~* For metastases in the central lung or mediastinal/ cervical lymph nodes, patients receive 5 fractions for a total of 50 Gy.~* For spinal metastases, patients receive 1 fraction of 20 Gy.~* For non-spinal osseous metastases, patients receive 3 fractions for a total of 30 Gy.~* For thoracic/cervical spine metastases, patients receive 5 fractions for a total of 35 Gy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: All surgical resections will be approached with intent of an R0 resection (rendering the patient with no evidence of measureable disease and pathologic negative margin) and must occur within 6 weeks of study entry. Approach to surgery will be based upon the treating surgeon. An open, laparoscopic, or thorascopic approach is acceptable.
Study: NCT01220531

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cultured Thymus Tissue
Description: Potential recipients of cultured thymus tissue are screened for eligibility. The thymus tissue (from an unrelated donor), the donor, and the donor's mother are screened for safety. Cultured thymus tissue is implanted under general anesthesia in the operating room. Cultured thymus tissue is placed into the subject's quadriceps. Two to three months post-implantation, if medically stable, subjects may undergo an allograft biopsy. Subjects undergo laboratory testing for approximately one-year post-implantation. At approximately year 2 post-implantation, subjects are contacted for data collection.
Study: NCT02846571

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Human Pancreatic Islet Transplantation
Description: Human pancreatic islet transplantation in the eye anterior chamber of legally blind patients with insulin-dependent type 1 or type 2 diabetes
Study: NCT03518606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab + Tremelimumab + metronomic Vinorelbine
Description: Patient will be treated by metronomic oral vinorelbine associated with durvalumab + tremelimumab combination immunotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab + Tremelimumab + metronomic Vinorelbine
Description: Patient will be treated by metronomic oral vinorelbine associated with durvalumab + tremelimumab combination immunotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab + Tremelimumab + metronomic Vinorelbine
Description: Patient will be treated by metronomic oral vinorelbine associated with durvalumab + tremelimumab combination immunotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab + Tremelimumab + metronomic Vinorelbine
Description: Patient will be treated by metronomic oral vinorelbine associated with durvalumab + tremelimumab combination immunotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab + Tremelimumab + metronomic Vinorelbine
Description: Patient will be treated by metronomic oral vinorelbine associated with durvalumab + tremelimumab combination immunotherapy
Study: NCT04362007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX660
Description: Treatment of ASTX660 for r/r PTCL and r/r CTCL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX660
Description: Treatment of ASTX660 for r/r ATLL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX660
Description: Treatment of ASTX660 for r/r PTCL
Study: NCT04326140

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mirror therapy
Description: The affected side wears the machine, assists by the machine, and performs the same action with the good hand. According to the posture condition, selects two suitable actions in the three actions (all fingers open, all fingers close, all fingers open and close). The action is 10 minutes each.
Study: NCT03167970

Intervention type: DEVICE
Intervention: Pill cam
Description: Patient is asked to swallow the esophageal capsule.

Intervention type: OTHER
Intervention: EGD
Description: Patient will undergo standard EGD
Study: NCT00619801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine
Description: Levocetirizine dihydrochloride 1.25 mg oral drops formulation (5 drops containing 5mg/mL) dosed twice a day for 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral drops (5 drops) dosed twice a day for 2 weeks.
Study: NCT04396431

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: education
Description: The intervention group was offered a six-hour training program based on the transtheoretical model in order to promote sun protection behavior and to reinforce self-efficacy. The program was prepared by the researchers in consideration of the SunSmart Program implemented in Australia, the SunWise School Program developed by the United States Environmental Protection Agency. The program included various educational tools such as a sun protection story, activity book, PowerPoint presentations, cartoons, and puzzles.~Refresher training was conducted 15 days, 1 month, and 2 months after the initial training. Sun protection behavior and self-efficacy of the children were evaluated at the beginning of the study and six months after the program. As gifts to support their sun protection behavior, the children were given an FDA-approved sunscreen with 50+ SPF, a white cotton short-sleeved T-shirt as protective clothing, sunglasses with 100% UV protection, and a wide-brimmed hat.
Study: NCT02172742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Description: BIA 2-093 1200 mg once-daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Digoxin (days 1 and 2: loading dose of 0.5 mg/day; days 3 to 8: 0.25 mg/day).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Digoxin
Description: Digoxin (days 1 and 2: loading dose of 0.5 mg/day; days 3 to 8: 0.25 mg/day).
Study: NCT01150981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: One 8mg capsule daily for 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule daily for 6 weeks.
Study: NCT01119885

Intervention type: DRUG
Intervention: fentanyl matrix
Description: Knee osteoarthritis, starting with 12mcg/h (flexible dose)

Intervention type: DRUG
Intervention: fentanyl matrix
Description: Hip osteoarthritis, starting with 12mcg/h (flexible dose)
Study: NCT04285879

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction using Delfi Personalized Tourniquet System
Description: The Delfi Tourniquet System is designed to be used in conjunction with exercise. The system automatically determines the degree of occlusion and allows for safe regulation of pressure. Patients will then complete exercises with the use of this device following the Owens Recovery Science Protocol
Study: NCT03330769

Intervention type: DRUG
Intervention: New course of treatment
Description: Prescription of new course of NSAIDs (monotherapy), steroid intra-articular injections (monotherapy), conventional DMARDs, biologic DMARDs, including switches or dose augmentations, indicated by the treating rheumatologist according to usual clinical practice.
Study: NCT03334851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo for PF-06835375 IV or SC. Subjects will receive one or two doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo for PF-06835375 IV or SC. Subjects will receive one or two doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo for PF-06835375 IV or SC. Subjects will receive one or two doses.
Study: NCT00503802

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Turbinate Reduction
Description: Radiofrequency Turbinate Reduction

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham RF
Description: The steps of the procedure are as follows: 1) application of topical anesthetic to the turbinate mucosa bilaterally; 2) injection of 1.0 ml of lidocaine 1% with epinephrine 1:100,000 with a 30-gauge needle into each inferior turbinate anteriorly; 3) delay five minutes for local anesthetic to take full effect; 4) re-insertion of the anesthetic needle to check for complete anesthesia on one side, and injection of another 1.0 ml of lidocaine 1% with epinephrine 1:100,000 5) placement of the radiofrequency electrode (23-gauge, 1 cm long) into the inferior turbinate; 6) delivery of 300 Joules of radiofrequency energy to the turbinate over 29 seconds (no energy will be delivered in sham procedure)7) placement of a cotton pledget (soaked in oxymetazoline solution 0.05%) against the treatment site 8) repeat steps 3 - 8 for the contra-lateral inferior turbinate; 9) removal of the cotton pledgets after several minutes; and 11) observation of hemostasis.
Study: NCT01948453

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Garlic
Description: Garlic tablet in adjunct to medical treatment
Study: NCT02388204

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantable spinal cord stimulation
Description: Implantation of SCS electrode and pulse generator

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantable spinal cord stimulation
Description: Implantation of SCS electrode and pulse generator
Study: NCT03728660

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual bioptic magnification with large field of view
Description: The intervention device will have a larger field of vision than the legacy device and the intervention device will also have a virtual bioptic telescope mode not found on the legacy device. The user will be able to adjust the size of the virtual bioptic telescope and the amount of magnification with a touch pad on the side of the head-mounted display (HMD).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual bioptic magnification with large field of view
Description: The intervention device will have a larger field of vision than the legacy device and the intervention device will also have a virtual bioptic telescope mode not found on the legacy device. The user will be able to adjust the size of the virtual bioptic telescope and the amount of magnification with a touch pad on the side of the head-mounted display (HMD).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Full field magnification with small field of view
Description: Comparison intervention with user-controlled full field magnification with a smaller field size shared by legacy head-mounted devices. User can control amount of magnification

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Full field magnification with small field of view
Description: Comparison intervention with user-controlled full field magnification with a smaller field size shared by legacy head-mounted devices. User can control amount of magnification
Study: NCT02419053

Intervention type: OTHER
Intervention: Surgical Safety Checklist
Description: An Ontario hospital-wide introduction of a surgical safety checklist based on the WHO guidelines, as mandated by the Ontario Ministry of Health
Study: NCT03334851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo for PF-06835375 IV or SC. Subjects will receive one or two doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo for PF-06835375 IV or SC. Subjects will receive one or two doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo for PF-06835375 IV or SC. Subjects will receive one or two doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo for PF-06835375 IV or SC. Subjects will receive one or two doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo for PF-06835375 IV or SC. Subjects will receive one or two doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo for PF-06835375 IV or SC. Subjects will receive one or two doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo for PF-06835375 IV or SC. Subjects will receive one or two doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo for PF-06835375 IV or SC. Subjects will receive one or two doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo for PF-06835375 IV or SC. Subjects will receive one or two doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo for PF-06835375 IV or SC. Subjects will receive one or two doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo for PF-06835375 IV or SC. Subjects will receive one or two doses.
Study: NCT04824235

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amniotic Chorion Membrane and Bio-Oss xenograft
Description: Bioxclude Amniotic Chorion Membrane with xenograft (Bio-Oss) for ridge preservation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Amniotic Chorion Membrane only
Description: Bioxclude Amniotic Chorion Membrane only